EntityRisk Review 2026: Health Economics Modeling

EntityRisk provides health economics expertise and PROVEN™, a software platform for biopharma and life-sciences teams. The company says the platform supports forecasting of health outcomes, value-based pricing, evidence investments and commercial revenue.

PROVEN™ is organized into five named tools: OutcomesML™, ValueML™, EvidenceML™, PriceML™ and CommercialML™. EntityRisk describes features for analyzing trial and real-world data, testing pricing and value scenarios, and adapting models across products and geographies. The company also says 10 of the top 20 biopharma companies work with it.

This is a specialized, business-to-business analytics service, not a crypto dApp. Pricing and access terms are not published, and the homepage does not detail software security controls or independent cybersecurity audits.

PROVEN™ is described as a modular software platform with a Python core for building disease-progression models. It combines health economics methods with machine learning and Bayesian approaches to simulate outcomes, pricing and commercial scenarios. EntityRisk says it can incorporate randomized controlled trial data, real-world data and target product profiles.

Its modules address different parts of product planning: OutcomesML™ models health outcomes; ValueML™ and PriceML™ estimate value, cost-effectiveness and prices; EvidenceML™ assesses the impact of evidence and product characteristics; and CommercialML™ forecasts revenue and downside risks. The company also says the platform supports multiple value frameworks and local adaptations of a shared model. Outputs are model-based estimates, so their usefulness depends on the inputs, assumptions and review applied by the customer.

Pricing and access fees are not published. Prospective customers need to contact EntityRisk to discuss commercial terms; the homepage does not list subscription tiers or usage charges.

EntityRisk describes model audit reports and automated checks intended to identify errors. These are quality-assurance features for analytics; they should not be treated as proof of an independent cybersecurity audit. The homepage does not publish details of security controls, data handling, access management or independent security certifications.

Forecasts are only as reliable as the data and assumptions behind them. Teams should validate model methods and outputs with qualified clinical, health economics and commercial reviewers before relying on them for pricing, investment or product decisions. EntityRisk does not present this service as a crypto application, and no token or on-chain custody model is described.

EntityRisk is aimed at biopharma and life-sciences organizations planning product development, pricing, market access or evidence generation. It is most relevant to teams with health economics expertise or access to reviewers who can assess model inputs and assumptions; it is not designed as a general-purpose consumer or crypto product.